CAR-T 细胞治疗市场战略、顶级参与者、增长机会、2030 年分析和预测

  • Report Code : TIPRE00029935
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

【研究报告】CAR-T细胞治疗市场规模预计将从2022年的27.9亿美元增至2030年的101.3亿美元;预计 2022 年至 2030 年复合年增长率为 17.5%。
市场洞察和分析师观点:
治疗癌症最有前途的方法之一是嵌合抗原受体 (CAR) T 细胞疗法,并且每年都会出现,进行了大量的临床前和临床试验以增加其应用。经过数十年的研究,CAR-T细胞疗法将不可避免地扩大。除了自体和同种异体产品外,未来的细胞治疗还将研究新的体内 CAR-T 细胞基因疗法及其对血液恶性肿瘤以外适应症的疗效。然而,商业化挑战阻碍了 CAR-T 细胞治疗市场的增长。
增长动力:
癌症患病率上升推动 CAR-T 细胞治疗市场
CAR-T 细胞治疗是一种新的癌症治疗方法。 T 细胞在实验室中经过修饰,然后返回体内以靶向癌细胞。成人和儿童白血病以及某些类型的淋巴瘤采用 CAR-T 细胞疗法进行治疗。此外,人们正在研究将其作为其他癌症的潜在治疗方法,例如胸部发生的一些实体瘤。
遗传倾向、加工食品、污染和生活方式的改变是导致癌症患病率增加的因素。据美国癌症协会统计,2020 年全球预计新增癌症病例 1,930 万例。因此,癌症患者数量的增加正在推动对 CAR-T 细胞疗法的需求。

报告细分和范围:
“CAR-T 细胞疗法市场分析”已考虑以下细分:目标抗原、适应症和最终用户。
细分分析:
按目标抗原, CAR-T细胞治疗市场分为CD19和BCMA。 CD19 细分市场将在 2022 年占据更大的 CAR-T 细胞治疗市场份额,预计在预测期内复合年增长率将达到 17.9%。
CAR-T 细胞可有效治疗复发/难治性弥漫性大 B 细胞淋巴瘤。来自患者的 T 细胞经过基因改造,可产生 CD19 CAR T 细胞。与白血病和淋巴瘤癌细胞中发现的高表达 CD19 蛋白结合的受体由修饰的 T 细胞表达。
CD19 CAR-T 细胞治疗产品的上市预计将推动该领域的增长。以下是分别在美国和欧洲获得美国食品药品监督管理局和欧盟批准的产品列表:
制造商
品牌产品
目标抗原
疾病适应症
批准年份< br>诺华
KYMRIAH
CD19
白血病
2017
吉利德科学公司
YESCARTA
CD19
淋巴瘤
2017
吉利德科学公司< br>TECARTUS
CD19
淋巴瘤和白血病
2020
百时美施贵宝
BREYANZI
CD19
淋巴瘤
2021
CAR-T 细胞治疗市场,按适应症分为淋巴瘤、白血病和多发性骨髓瘤。淋巴瘤细分市场到 2022 年将占据更大的市场份额,预计在预测期内复合年增长率将达到 18.1%。急性淋巴细胞白血病、慢性淋巴细胞白血病、淋巴瘤、多发性骨髓瘤等血液恶性肿瘤一直是CAR-T细胞使用的主要适应症。
CAR-T细胞治疗市场按最终用户划分为医院以及专科诊所、门诊手术中心等。医院和专科诊所细分市场在 2022 年占据最大的市场份额,预计在预测期内复合年增长率最高,达到 17.9%。
按靶向抗原划分的 CAR-T 细胞治疗市场 – 2022 年和 2030 年
技术加速 CAR-T 细胞疗法市场扩张的进步
CAR-T 疗法的创建和引入,利用患者的白细胞来对抗特定形式的血癌细胞,是过去几年最伟大的医学进步之一。一些癌症患者可能会在 CAR-T 细胞疗法中找到希望作为潜在的治愈方法。自 2017 年批准第一种疗法用于治疗特定类型的成人和儿童白血病、淋巴瘤和多发性骨髓瘤以来,美国食品和药物管理局 (FDA) 又批准了另外五种 CAR-T 细胞疗法。我们还在开展研究,以创造针对实体瘤的类似治疗方法。
同种异体 CAR-T 细胞疗法已成为全球数百项临床前和临床试验的主题。其中大多数用于治疗血液恶性肿瘤,其中 CD19 是最常用的靶标,以及其他传统靶标,例如 CD20、CD22 和 BCMA。还包括新开发的靶标,例如 CD70、CD7 和 CD5。实体瘤的新兴治疗方法包括间皮素、GD2 和 NKG2DL。
因此,基于细胞的疗法的进步可能会在未来几年带来新的 CAR-T 细胞治疗市场趋势。
区域分析:
全球CAR-T细胞治疗市场报告的范围主要集中在北美、欧洲、亚太地区、南美洲和中美洲以及世界其他地区。 2022年,北美占据最大的CAR-T细胞治疗市场份额。该地区的市场增长是由主要制造商推出的产品数量不断增加以及主要市场参与者的存在推动的。此外,各种制药和生物技术公司以及学术和研究机构的广泛研发预计将刺激北美市场的增长。例如,2022年6月,百时美施贵宝宣布获得美国食品和药物管理局(FDA)批准的Breyanzi(lisocabtagene maraleucel),这是一种针对CD19的CAR-T细胞疗法,用于治疗患有大B细胞的成年患者细胞淋巴瘤 (LBCL),包括弥漫性大 B 细胞淋巴瘤 (DLBCL)。
在美国,CAR-T 细胞疗法市场的增长主要由不断增长的制药和生物制药行业推动,其特点是技术进步和灵活性增强。此外,美国制药和生物技术公司增加研发投资,以改善临床试验结果并确保患者安全,从而刺激市场增长。例如,2021年7月,BioNTech SE与吉利德公司旗下Kite签署了一份购买协议,允许BioNTech购买Kite位于马里兰州盖瑟斯堡的临床生产设施及其实体瘤新抗原T细胞受体(TCR)研发平台。新的盖瑟斯堡工厂补充了 BioNTech 目前位于德国伊达尔-奥伯施泰因的细胞治疗生产设施,并提供了加强美国临床试验的生产能力。该设施有助于推进公司不断增长的创新细胞疗法产品线,其中包括基于 NEOSTIM 和 CAR-T 细胞扩增 mRNA 疫苗 (CARVac) 的癌症候选产品以及最近收购的个体化 Neoantigen TCR 项目。
未来的机遇和研究进展:
CAR-T 细胞疗法在癌症治疗中显示出有希望的结果;然而,它们的使用仅限于患有某些复发且耐药的液体肿瘤的患者。未来几年,美国再生医学的几种 CAR-T 细胞疗法和欧洲的先进治疗医疗产品预计将获得市场授权。数百种具有创新技术的不同关键参与者正在开发用于广泛的适应症。从长远来看,这些治疗方法可以通过单剂量提供实质性的、甚至是治愈性的健康优势来改善患者的治疗结果。
考虑到正在进行的临床试验和新 CAR 的数量,CAR-T 细胞治疗的未来非常有希望-正在开发针对一系列适应症的T细胞产品。由于在先前接受过大量治疗的复发/难治性恶性肿瘤患者中观察到完全缓解率和无进展生存期,研究人员有动力研究提高 CAR-T 细胞有效性的方法。
研究人员正在研究抗原丢失等因素可能会导致免疫逃逸,我们正在想办法应对它们。创建同时靶向多种抗原的 CAR-T 细胞疗法就是这样的策略之一。正在开发针对 CD138 和 GPRC5D 等抗原的新药物。相比之下,针对 ALL 和 NHL 的 CAR-T 细胞治疗以 CD19 抗原为目标,而针对多发性骨髓瘤的治疗则以 BCMA 抗原为目标。
CAR-T 细胞治疗市场预测可以帮助该市场的利益相关者规划其增长战略。下面列出了 CAR-T 细胞治疗市场领先企业的一些研发成果:
2023 年 11 月,Vittoria Biotherapeutics 宣布完成一轮私募融资,筹集超过 1500 万美元。这些资金将用于开展 VIPER-101 的临床试验——一种用于治疗 T 细胞淋巴瘤的自体双群体 CD5 敲除 CAR-T 细胞疗法。
2023 年 12 月,阿斯利康宣布收购 Gracell Biotechnologies Inc.,以补充阿斯利康的业务细胞疗法的现有能力和之前的投资。
2021 年 12 月,加州大学圣地亚哥分校医学院(美国)的研究人员获得了 410 万美元的资助,以支持其创新 CAR-T 细胞疗法的进展。这笔资金由加州再生医学研究所(美国)理事会授权,可能使该集团能够将新型癌症治疗从实验室推进到患者的床边。
竞争格局和主要公司:
布里斯托尔-迈尔斯施贵宝公司;诺华公司;吉利德科学公司;强生服务公司;科思杰生物科技有限公司;奥罗拉生物制药;传奇生物科技;辉瑞公司;蓝鸟生物公司;野马生物;索伦托治疗公司;和 Fate Therapeutics 是 CAR-T 细胞疗法市场报告中介绍的知名公司之一。这些公司专注于开发新技术、升级现有产品并扩大其地域分布,以满足全球不断增长的消费者需求。
  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Global, Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is CAR-T cell therapy market?

Chimeric antigen receptor (CAR)-T cell therapy is a kind of cancer immunotherapy treatment that makes use of T cells, which are immune cells, that have undergone genetic alteration in a lab to improve their ability to recognize and eliminate cancer cells. CAR-T cell therapy is one of the newest and most promising treatments for blood cancer.

What are the driving factors for the CAR-T cell therapy market across the globe?

Key factors that are driving the growth of this market are new product approvals and increase in prevalence of cancer is expected to boost the market growth for the CAR-T cell therapy over the years.

Which product segment leads the CAR-T cell therapy market?

The CD19 segment held the largest share of the market in the global CAR-T cell therapy market and held the largest market share in 2022.

What is the market CAGR value of CAR-T cell therapy market during forecast period?

The CAGR value of the CAR-T cell therapy market during the forecasted period of 2022-2030 is 17.5%s

Which application segment held the largest share in the CAR-T cell therapy market?

The Lymphomas segment dominated the global CAR-T cell therapy market and held the largest market share in 2022.

Which are the top companies that hold the market share in CAR-T cell therapy market?

Gilead Sciences, Inc and Bristol Myers Squibb are the top two companies that hold huge market shares in the CAR-T cell therapy market.

Which region is expected to witness significant demand for CAR-T cell therapy market in the coming years?

Global CAR-T cell therapy market is segmented by region into North America, Europe, Asia Pacific, Rest of World. North America held the largest market share of the CAR-T cell therapy market in 2022.

Who are the key players in the CAR-T cell therapy market?

The CAR-T cell therapy market majorly consists of the players such Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., CARsgenTherapeutics Co., Ltd, Aurora Biopharma, Legend Biotech, Pfizer Inc., bluebird bio, Inc., Mustang Bio, Sorrento Therapeutics, Inc., and Fate Therapeutics, and amongst others.

Trends and growth analysis reports related to Life Sciences : READ MORE..   
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

The List of Companies - CAR-T Cell Therapy Market

  1. Bristol-Myers Squibb Company
  2. Novartis AG
  3. Gilead Sciences, Inc.
  4. Johnson & Johnson Services, Inc.
  5. CARsgenTherapeutics Co., Ltd
  6. Aurora Biopharma
  7. Legend Biotech
  8. Pfizer Inc.
  9. bluebird bio, Inc.
  10. Mustang Bio
  11. Sorrento Therapeutics, Inc
  12. Fate Therapeutics

Buy Now  

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.